source
- Estuary sails into kidney disease space with $103M for gene therapiesEstuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.BioSpace · 4d ago↗ source
- OrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaThe sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.BioSpace · 4d ago↗ source
- AstraZeneca teams with insitro in up to $1.5 billion AI partnership to target MASH and cardiomyopathiesAstraZeneca announced a partnership with AI-driven biotech insitro, committing up to $1.5 billion to discover new drug targets for metabolic dysfunction-associated steatohepatitis (MASH) and cardio…